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ABSTRACT
Background and the purpose of the study: Because of its intense bitter taste and susceptibility to 
moisture Cefetamet Pivoxil (CPH) is presently available only in the form of  tablet. The aim of 
this study was to develop  taste masked CPH dry powder suspension. 
Methods: Methods employed for formulations were: a) Film coating of CPH using Eudragit 
E100 and subsequent adsorption on different carriers such as spray-dried lactose, sodium 
starch  glycolate  and  spray-dried  mannitol  and  b)  Complexation  of  CPH  with  three  different                        
ion exchange  resins indion 234 amberlite IRP64 and amberlite IRP69. 
Results: Taste viz evaluation as recognized by volunteers revealed that coating with Eudragit 
E100 and subsequent adsorption on different carriers do not mask the bitter taste of the drug. 
Suspensions prepared using amberlite IRP64 and amberlite IRP69 were extremely palatable 
with no bitter after taste. They showed pseudoplastic flow behavior and were too viscous even 
after shearing for sufficient duration of time and exhibited poor pourability. The suspension 
made with indion 234 was palatable with slight or no bitter after taste. It demonstrated plastic 
flow with negligible thixotropy. It had moderate viscosity at rest and could be poured after a 
reasonable amount of shaking. CPH dry powder suspensions were very unstable under different 
conditions except under refrigeration. A 5% degradation of drug was occurred in reconstituted 
suspension in 4 days period when stored at room temperature. 
Conclusion: Dry powder suspension prepared with indion 234 having 5% overages was stable 
even after 4th day of reconstitution and palatable with slight or no bitter after taste.
Keywords: Complexation, Indion 239, Thixotropy, Eudragit E100.
DARU Vol. 19, No. 2 2011
Correspondence: sbsateesh@gmail.com
INTRODUCTION
Cefetamet pivoxil hydrochloride (CPH, Fig 1) is an 
oral third generation cephalosporin antibiotic. The 
active form of the CPH is cefetamet which is formed 
invivo by hydrolysis (1). Cefetamet has excellent 
invitro activity against major respiratory pathogens 
like  Streptococcus  pneumoniae,  Haemophilus 
influenzae,  β-haemolytic streptococci,  Neisseria 
gonorrhoeae, Enterobacteriaceae. and H. influenza 
(2). It is effective in the treatment of otitis media, 
pneumonia and in pharyngotonsilitis (3). CPH 
is also used in the treatment of both upper and 
lower community acquired respiratory tract and 
complicated urinary tract infections in children and 
elderly patients (4). 
Presently CPH is formulated and marketed only 
in the form of tablet because of its intensive bitter 
taste and instability when stored in liquid form (5). 
In general better patient compliance in the case of 
pediatrics and geriatrics can be achieved if the drug 
is formulated as a liquid dosage form. However 
formulation of liquid suspension of CPH is not 
advisable because of its instability in the presence of 
water (6). So, development of stable and palatable 
dosage form of CPH is a real challenging job. 
In the present work a well known film coating agent 
Eudragit E100 (7) and three cationic resins viz., 
indion 234 (8), amberlite IRP64 (9) and amberlite 
IRP69 (10) were evaluated for their abilities to 
improve the palatability of CPH and its protection 
against adverse atmospheric conditions. They are 
high molecular weight cross-linked polymers and 
therefore not absorbed by body tissues and are 
totally safe for human consumption (11). It is well 
documented that the complexation of drugs with 
these polymers are stable at the pH of saliva i.e., 
6.7 and at cation concentration (40 mEq/l) of saliva. 
At the same time the complex is weak enough to 
be broken down at the pH 3 or lower (pH of the 
stomach). Thus the complexation of drug with these 
polymers and its development into a dry powder 
suspension was considered to give a stable and 
118palatable for the perception of the tongue (12). 
MATERIAL AND METHODS
Materials
CPH (Alembic Ltd. Vadodara, India), indion 234, 
amberlite IRP64 and amberlite IRP69 (Recon Ltd. 
Bangalore, India) were received as gift samples. 
Eudragit E100 was supplied by Corel Pharma-
Chem. All other chemicals used in the study were 
laboratory grade. 
Methods
Incompatibility studies
Drug and excipients of the formulation were analyzed 
for compatibility using thin layer chromatography 
(TLC) technique. Drug and excipients were mixed 
at 1:1 ratio and stored for 3 months in glass vials 
at 50°C. Samples were analyzed after 24 hrs and 
at the end of 3 months storage. Ten microliter of 
samples dissolved in methanol was applied on thin 
plate of silica gel GF254 and chromatogram was 
developed using a mobile solvent system consisting 
a mixture of benzene, methanol and ammonia 
(30:10:1). TLC was examined under UV light at 254 
nm and Rf values  were  calculated  using  the  formula,                     
Rf=Distance travelled by the compound/Distance 
travelled by the solvent front
Preparation of CPH microspheres
Eudragit E100 was dissolved in 200 ml of the 
mixture of ethanol and water (6:4). The drug was 
previously passed through sieve #100 and dispersed 
into polymer solution by heating on the water 
bath. Thirty grams of carrier, spray-dried lactose, 
sodium starch glycolate (SSG) and spray-dried 
mannitol were added in three separate batches. The 
whole mixtures was mechanically stirred for 10 
min at the speed of 900 rpm using a stirrer (RQ-
127A) fitted with a 4-blade impeller. The resulting 
CPH-polymer carrier adsorbate was air-dried at 
ambient temperature in the laboratory for 24 hrs 
and conditioned over calcium sulphate granules 
(Drierite(R)) in a desiccator overnight and passed 
through sieve #30 to give free flowing microspheres 
(13). 
Preparation of CPH granules
Complexation of CPH with resins was carried out at 
different drug to resin ratio (1:1, 1:2, 1:3, and 1:4) 
for all resins. Resin was added in to water and stirred 
on magnetic stirrer for 30 min and left to equilibrate 
for another 30 min to obtain resin slurry. Aqueous 
drug dispersion was added in small quantities to the 
resin slurry and stirred continuously at 600 rpm for 
4-5 hrs (14). The drug resin complex (DRC) thus 
obtained was washed on buchner funnel with 500 ml 
deionized water to remove unbound drug. Washings 
were digested with known amount of acetonitrile. 
The concentration of unbound drug was estimated 
by the analyses of washings by HPLC and drug-
loading efficiency was calculated. DRC was dried at 
50°C in an oven for 24 hrs or untill granular residual 
moisture content falls to 5%. The DRC was milled 
and sifted through sieve #60 to obtain free flowing 
granules. 
Dry powder suspension (DPS) formulation
Microspheres and granules prepared above were 
blended separately with the ingredients shown 
in table 1 for 10-15 min. Formulations (8 doses) 
were filled into amber colored bottles, labeled and 
stored between 2-8°C till further studies. DPS was 
reconstituted by addition of 40 ml of purified water 
with agitation.  
Assay
The drug content of 1) CPH-polymer-carrier 2) 
CPH-resin complex 3) DPS and 4) reconstituted 
suspension (RS) on the days of 1 and 4 were 
determined by HPLC method (15) using Shimadzu 
CLASS-VP V6.12 SP4 chromatograph equipped 
with Inertsil, ODS, C18, 150x4.6 mm, 5 µ column. 
The chromatogram was obtained by injecting 20 µl 
of the solution of CPH in acetonitrile and water mixture 
(1:1). The flow rate was adjusted to 1 ml/min and UV-
Visible spectrophotometer set to 264 nm was used 
as detector. The calibration curve was found to be 
linear (R2=1) at the concentrations of 25 and 200 µg/ml. 
The calibration curve of CPH in 0.1N HCl which 
was developed using UV-Visible spectrophotometer 
at  264  nm  showed  linearity  from  4  µg/ml  to  24           
µg/ml. The working curve equation was y=0.0329x 
with  correlation  coefficient  value  of,  r2=0.9999. 
Solutions were sonicated and filtered through 0.45 µ 
(Millipore) membrane filter prior to analysis.
Physical properties 
Powder properties (16) were measured for DPS 
using tap density tester (Electrolab ETD-1020). The 
angle of repose was measured by fixed cone method. 
pH of RS was measured on the days of 1 and 4 at 
25°C using a digital pH meter. The specific gravity 
(Sp.gra)  of  the  RS  was  determined  in  a  specific 
gravity bottle at 25°C using following formula,
Sp.gra=Weight of the RS/ Weight of an equal volume 
Figure 1. Molecular structure of cefetamet pivoxil hydrochloride.
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of water (reference standard)
Carr’s compressibility index and the Hausner ratio 
were determined to provide a measure of flowability 
of powder (16).
Dissolution studies 
Dissolution studies (17) were performed for a 
total period of one hour in USP 24 type-II (Paddle 
method) apparatus at 50 rpm. DPS equivalent to 200 
mg of CPH was transferred to 500 ml of 0.1N HCl 
solution maintained at 37±0.5°C and 5ml sample 
was withdrawn at regular intervals during one 
hour,  replaced with the same volume of prewarmed 
(37±0.5°C) fresh dissolution medium and were 
analyzed using UV-Visible spectrophotometer. 
Palatability test 
The gustatory sensation tests were performed in six 
healthy human volunteers (20-25 years). The test was 
approved by the institutional human experimentation 
committee (Proposal No. VIPS/872/2/09-10). 
To find a suitable concentration for the evaluation 
of the bitterness intensity during the comparative 
test, 6 standard dispersions of drug in water at 
concentrations of 0, 10, 20, 30, 40 and 50 µg/ml 
were prepared. Human volunteers were asked to held 
5 ml of aqueous dispersion of CPH in their mouth 
and bitterness recognition threshold of pure drug 
was evaluated (18). The bitterness level of RS was 
recorded against standard dispersions of drug using a 
numerical scale (19). Human volunteers were asked 
to taste 5 ml of RS. Then, they were required to give 
one of these graded perceptions; Palatable with no 
bitter after taste=0, Palatable with slight bitter after 
taste=1, Quite palatable with bitter after taste=2 and 
Very unpalatable with bitter after taste=3.
Rheological studies
The sedimentation volumes were determined for 50 
ml of each suspension at intervals of one day and up 
to seven days. The sedimentation volume F (%), was 
calculated using the formula F=100Vu/Vo, where Vu 
is the volume of the sediment and Vo is the original 
volume.
The rheological studies were conducted for 8 
ml of RS at 25°C using Brookfield DV-II+ Pro 
EXTRA viscometer with spindle SC4-18. Spindle 
speed was varied for ascending and descending 
modes by change of 10 rpm/min. Rheograms 
were constructed and rheological properties were 
measured (20, 21). 
Stability studies
DPS and RS of F4, F5 and F6 were subjected to 
stability studies. Formulations were packed and 
sealed in amber colored glass bottles and kept for one 
month storage at 28±2°C, 40±2°C, 50±2°C, 60±2°C 
and under refrigeration condition of 2-8°C at ambient 
humidity conditions. Preparations were analyzed for 
the change in drug content and appearance at periodic 
intervals of time for 1, 2 and 4week. FTIR analysis 
was also employed to quantify interaction between 
indion 234 and CPH using Shimadzu 8400S FTIR 
spectrophotometer (Kyoto, Japan).
Formulation ingredients
Formulation code
F1 F2 F3 F4 F5 F6
Cefetamet pivoxil hydrochloride 
Eudragit E100
Spray dried lactose
Sodium starch glycolate
Spray dried mannitol
Indion 234
Amberlite IRP64 
Amberlite IRP69
Avicel CL611
Aspartame
Monobasic  sodiumphosphate
Dibasic sodium phosphate 
Bronopol (dried)
Trusil orange flavor 
Methyl paraben
Propyl paraben
1.6
2
3
-
-
-
-
-
1.2
0.3
0.04
0.42
0.12
0.01
0.02
0.01
1.6
2
-
3
-
-
-
-
1.2
0.3
0.04
0.42
0.12
0.01
0.02
0.01
1.6
2
-
-
3
-
-
-
1.2
0.3
0.04
0.42
0.12
0.01
0.02
0.01
1.6
-
-
-
-
4.8
-
-
-
0.18
0.04
0.42
0.12
0.01
0.02
0.01
1.6
-
-
-
-
-
4.8
-
-
0.18
0.04
0.42
0.12
0.01
0.02
0.01
1.6
-
-
-
-
-
-
4.8
-
0.18
0.04
0.42
0.12
0.01
0.02
0.01
aAll quantities are in grams 
b Drug to resin (D:R) ratios  for F4, F5 and F6 were 1:3 
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RESULTS AND DISCUSSION
Formulation development
In this investigation different formulations of CPH 
were developed using various excipients to mask 
their bitter tastes. All excipients selected for the 
formulation  were compatible with the drug as it was 
confirmed by the Rf values of TLC studies (Table 2). 
Microspheres of CPH prepared using eudragit E100 
and subsequent adsorption on to different carriers 
were uniform, smooth in their surfaces and were free 
flowing as evident from the flow properties shown in 
table 3. Granules prepared with resin were irregular 
in shape, hard, and rough in texture depending 
to  resin  concentration  and  showed  average  flow 
property and poor packing arrangement (Table 3). 
Drug-resin ratio of (D;R) of 1:3 was found to be 
the minimum for giving maximum drug loading 
efficiency with moderate viscosity. The formulations 
made with amberlite IRP64 and amberlite IRP69 had 
relatively higher viscosities even at 1:3 (D: R) ratios. 
Further, these preparations were slightly brown 
colored due to the color of the resin itself. 
Drug content of DPS and RS on the first day found to 
be 96.23 to 98.45%  respectively.  The drug release 
from all formulations were 90% or higher within 
5  min  (Fig  2)  which  confirms  that  complexation 
process does not affect the release of drug from DRC 
at the pH of stomach. 
For all formulations, pH were maintained above 6 
and specific gravity were within the desired range 
(>1) even after 4th day of reconstitution which 
confirms that DPC was intact during storage period 
(Table 4). 
Palatability test
The perception and bitterness recognition of pure 
drug from the majority of volunteers was found 
to be 50 µg/ml. Taste evaluation (Table 5) as 
recognized by volunteers revealed that coating 
with Eudragit E100 and subsequent adsorption 
on different carriers does not mask the bitter 
taste of the drug. Microspheres adsorbed on to 
mannitol were relatively palatable with bitter 
after taste and compared to drug-resin-complex 
Component (1:1 mixture) Rf values  (After 24 hrs) Rf values (After 3 months)
Pure drug
CPH+ Spray dried lactose
CPH+ SSG
CPH+ Spray dried mannitol
CPH+ Eudragit E100
Drug + Indion 234
CPH+ Amberlite IRP64 
CPH+ Amberlite IRP69
Drug+ Myristic acid
Drug+ Bronopol
Drug+ Aspartame
Drug+ Sucrose
Drug+ Tutti fruti flavor
Drug+ Propyl paraben
Drug+ Ethyl paraben
0.673
0.64
0.67
0.65
0.672
0.671
0.65
0.64
0.669
0.67
0.65
0.675
0.66
0.67
0.67
0.67
0.65
0.66
0.65
0.668
0.66
0.66
0.65
0.659
0.671
0.645
0.653
0.67
0.66
0.65
Physical properties
Formulation code
F1 F2 F3 F4 F5 F6
Bulk density (g/cc)
Tapped density (g/cc)
Carr’s index
Hausner ratio
Angle of repose, θ
Assay of dry powder suspension (%)
0.550
0.561
18.95
1.24
24.70°
97.23
0.567
0.734
18.94
1.232
26.27°
97.09
0.574
0.719
18.88
1.234
28.33ο
96.23
0.541
0.721
19.21
1.226
24.40°
98.15
0.553
0.715
19.22
1.231
23.40°
98.45
0.564
0.717
20.07
1.219
25.40°
97.15
aValues are average of 3 determinations (n=3)
Table 2. Rf values of mixture of CPH and excipient determined by TLC study.
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Formulation code
Sedimentation volume % pH of the formulation Specific gravity  Results of the assay of formulation (%)
Day 1 Day 7 Day 1 Day 4 Day 1 Day 4 Day 1 Day 4
F1
F2
F3
F4
F5
F6
57
59
56
59
63
67
51
50
52
54
63
65
6.21
6.16
6.21
6.72
6.83
6.79
6.25
6.14
6.12
6.63
6.67
6.68
1.22
1.13
1.03
1.53
1.76
1.78
1.19
1.12
1.01
1.48
1.73
1.74
97.13
97.08
96.02
98.02
98.25
97.15
91.01
92.81
91.14
93.12
92.35
91.88
aValues are average of 3 determinations (n=3)
Table 4. Physical characteristics of reconstituted suspension.
Formulations
Volunteer opinion
1 2 3 4 5 6
Pure drug
F1
F2
F3
F4
F5
F6
3
2
3
2
1
0
0
3
3
2
2
0
0
0
3
2
2
2
0
0
0
3
2
3
2
1
0
0
3
2
2
2
0
0
1
3
3
2
2
1
0
0
aValues are average of 3 determinations (n=3)
Table 5. Bitterness evaluations by taste panel.
Figure 2.
Figure 2. Dissolution profile of CPH formulations at various times.
were less palatable and therefore were withdrawn 
from further studies. Suspensions prepared using 
amberlite IRP64 and amberlite IRP69 were 
extremely palatable with no bitter after taste and 
formulation made with indion 234 was palatable 
with slight or no bitter after taste. 
Rheological studies
All formulations had high sedimentation volume, 
which  indicated  drug  particles  formed  flocs. 
Rheograms of formulations F4, F5 and F6 are shown 
in figure 3. The hysteresis loop area indicates the 
extent of structural breakdown and time for recovery. 
Formulation  F4  demonstrated  plastic  flow  with 
negligible thixotropy and additionally, no hysteresis 
effect (Fig 3a). This is due to the possible breakdown 
in structure which might reform immediately during 
the flow system. Formulations F5 and F6 showed 
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Figure 3. Rheological behavior of formulations F4, F5 and F6
pseudoplastic flow behavior, whose loop areas were 
relatively high compared to F4 (Fig 3b). 
Steady shear flow behavior observed with F4 was 
minimum compared to F5 and F6 formulations as it 
is shown in figure 3c. This means that subjecting a 
material to stress less than the yield stress will lead 
to a nonpermanent deformation. Formulation F4 had 
moderate viscosity at rest and it could be poured 
after a reasonable amount of shaking. Formulation 
F5 and F6 were too viscous even after shearing 
for sufficient duration of time and exhibited poor 
pourability. 
Stability studies 
CPH dry powder suspensions were very unstable 
under different storage conditions except 
refrigeration. There were a decrease in drug content 
by 5 to 10% in all formulations when stored at 
*
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Legends
Figure 1: Molecular structure of cefetamet pivoxil hydrochloride 
Figure 4. FTIR spectra of cefetamet pivoxil hydrochloride and its physical mixture with resin indion 234.
28±2°C for 1 month. A 5% degradation of drug was 
occurred in RS in 4 days period at room temperature. 
Hence the formulations of CPH with 5% overages 
are  recommended.  FTIR  studies  confirmed 
complexation stability of CPH with indion 234       
(Fig 4). 
CONCLUSIONS  
The results of this work showed that microspheres 
prepared with Eudragit E100 and subsequent 
adsorption on carriers doesn’t improve palatability 
of CPH. Formulation with amberlite IRP64 and 
IRP69 were palatable but had high viscosity upon 
reconstitution. DPS prepared with resin indion 234 
having 5% overages was palatable and stable even 
after 4th day of reconstitution at room temperature. 
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